Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

About this update from Transcenta Holding Limited

[{"type":"text","content":"PRINCETON, N.J. and SUZHOU, China, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced that members of its senior leadership team will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference February 25-26, 2026.","length":483,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"max-width:20%;min-width:20%;","val":[{"type":"text","content":"36th Annual Oppenheimer Healthcare Life Sciences Conference","length":59,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:25%;width:25%;min-width:25%;","val":[{"type":"text","content":"Format:","length":7,"tagName":"p","attribs":{}}]},{"style":"max-width:75%;width:75%;min-width:75%;","val":[{"type":"text","content":"Virtual presentation and one-on-one investor meetings","length":53,"tagName":"p","attribs":{}}]}]},{"val":[{"val":[{"type":"text","content":"Presentation Date and Time:","length":27,"tagName":"p"}]},{"val":[{"type":"text","content":"February 26, 2026, 12:00pm Eastern Time","length":39,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Attendees:","length":10,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Xueming Qian, Founder, Chairman and CEO","length":43,"tagName":"p"}]}]},{"val":[{"val":[]},{"val":[{"type":"text","content":"Mr. Weiwei Liang, SVP, Business Development and Corporate Strategy; Acting CFO","length":78,"tagName":"p"}]}]},{"val":[{"val":[]},{"val":[{"type":"text","content":"Mr. Tyler Marciniak, SVP, Capital Markets, Investor Relations & Corporate Communications","length":92,"tagName":"p"}]}]}],"length":410},{"type":"text","content":"During the conference, management will discuss with investors its strategic efforts for 2026 and provide updates on its ongoing business development and operational excellence initiatives.","length":188,"tagName":"p"},{"type":"text","content":"About Transcenta TherapeuticsTranscenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.","length":228,"tagName":"p"},{"type":"...

More updates from Transcenta Holding Limited